Roberto Carminati and Caterina Lucchini 
During a recent online seminar Frost & Sullivan’s analysts and experts wondered whether the so-called Bric area can indeed be the saviour for the life sciences and medical devices sector; or not. There is no doubt in fact that Brazil, Russia, India and China still represent a huge market opportunity for pharmaceutical companies from all over the western world but still they need to be handled with care.
Roberto Carminati and Caterina Lucchini
Despite the fact it recently announced that the Gross domestic product (Gdp) targets it aimed to reach are not going to be hit in the short-medium period, China still displays huge opportunities of growth and business for players in the pharmaceutical arena coming from the western world. This is also what experts and analyst participating a mid-spring online seminar held by Frost & Sullivan clearly stated; whilst on the other hand giving their audience a few hints and advices about the pro’s and con’s of operating in the critical Popular republic industry and market. Dedicated to the whole so called Bric area including Brazil, Russia and India too, the webinar was hosted by Reenita Das together with Siddharth Saha, Eduardo Golisano, Glenn Hou and Sandeep Sinha. And it displayed how all along the Great Wall economy in general and the pharmaceutical industry are still growing at a rapid pace and offer corporate and researches good chances to succeed, should they develop a correct and tailor-made business model.
EU enlargement is a progress toward harmonisation of marketing authorisations of medicinal products in the European Union and European Economic Area. Community pharmaceutical legislation fully harmonises the standards for quality, safety and efficacy of a medicinal product, making any authorisation granted by one Member State generally recognizable by the other Member States. Starting from July 1st 2013, Croatia will be fully part of this system, making easier for the Companies a full regulatory harmonisation in the European Territories
Ida Caramazza
European Union (EU) has progressively enlarged throughout the last decades. Successive accessions have seen the number of members gradually increase from the original six to twenty seven. On 9 December 2011 leaders from the EU and Croatia signed the accession treaty, so that Croatia will become the 28th EU member country on 1 July 2013. Starting from that date, medicinal products market in Croatia will be regulated according to Europan Union laws.
People around 50-60 years old lived through two revolutions. No, we do not talk about politics, we are talking about sexuality. The first revolution, the one of free love, took place from the sixties onwards and had “the Hippies” as main characters, while the second, much more recently, did not have people as protagonists, but a pill, a little blue pill. The Viagra. Born to have a role completely different from what then it took over, Viagra has revolutionized the way of thinking to erectile dysfunction. In Italy, second European Country (after UK) in terms of sales, patent protection of the “pill of love” expires this June, we will see the effects
Eros Fabrizi
In the comedy “love and other drugs” Maggie (Anne Hathaway) and Jamie’s (Jake Gyllehaal) evolving relationship takes them both by surprise, as they find themselves under the influence of the ultimate drug, love. This would be pretty common if Jamie was not a pharmaceutical rep, responsible for the commercialization of the newborn “pill of love” Viagra in nineties. In that times, in fact, Pfizer had just released on the market the first and most famous treatment for erectile dysfunction. This was not only an innovation in terms of possibility to address unmet medical needs, but first of all a breakthrough for that part of male (and also female!) population that, for many reason, had lost their sexual happiness.
M. Radice (1), G. Talamini (2), F. Faccioli (3), and G. Coppi (4)
(1) Industriale Chimica, 21047 Saronno (VA), Italy; (2) Toxicological Work Group, IRCCS, Fond. Maugeri, University of Pavia (Italy); (3) Eurofins Biolab S.r.l., 20090 Vimodrone (MI), Italy; (4) Consultant AFI, Assoc. Farmaceut. Indust., (MI), Italy
Genotoxicity testing of therapeutic drugs is generally used for hazard identification with respect to DNA damage and its fixation (1). These damages can be manifested in the form of gene mutation, and these changes are responsible for heritable effects on germ cells and impose risks to future generations (2). In addition, it has been well documented that somatic mutations can also play an important role in malignancy (3).
Paolo Mazzoni, PTM Consulting
We usually do not need the process map per se, but mainly as a starting point for further analysis. Any mistake or weakness in the process representation may jeopardize the entire effort of achieving comprehensive process knowledge. It is important to appreciate that process mapping is the basis for process modelling or simulation, including risk analysis or statistical simulation.
Providing services with high added value, through integrated and evolved concept by Contract Manufacturing is the mission of Corvette Group Pharmaceutical Services which includes companies with specialized skills and extensive experience in pharmaceutical outsourcing
Giovanni Bernuzzi
Corvette Group Pharmaceutical Services, established in 2009, is a holding company in the pharmaceutical industry that sets its own strategy on the acquisition of cutting-edge companies with deep technical and production know-how which is the final result of decades of experience in the pharmaceutical industry, and that work exclusively for third parties. Biologici Italia Laboratories is the first company acquired by the Group in December 2009. Specializing in the production of injectable sterile liquid and lyophilisated products, the company’s history started during the ‘70s thanks to Dr. Filippo Serpero. A year after, in December 2010 the Group acquires Liosintex established in 1973, which provides services in bulk lyophilization for beta-lactam antibiotics, penicillin and cephalosporin. In July 2011 the Group acquires Edmond Pharma, established in the ‘70s and producing and developing Erdosteine, active substances and finished generic products.
“Giving substance to your ideas”: these words sum up the commitment to its customers by Novinox, a company that for over 50 years, has been designing, manufacturing and installing equipment for pharmaceutical, cosmetics, chemical and food industries
Giovanni Bravo
Novinox s.r.l. was established in 1956 by Angiolino Bonvini, joined in the ‘70’s by his son, Alfredo Bonvini, who is the current President. He himself, in the company’s headquarters in Nova Milanese, introduces the company to Pharma World Magazine readers together with his sons Fabio and Daniele, representing the third generation of the family of entrepreneurs: «Initially directed to the petrochemical sector, since the early 60’s, the activity has pointed to the pharmaceutical industry, which since the 70’s, in conjunction with my entry in the company, has become Novinox core business».
As a result of its high standards of quality, innovative technologies and clear vision for the future, Aenova has become one of the world’s leading companies for the development, manufacture and marketing of solid, semi-solid and liquid dosage forms
Giovanni Bernuzzi
Aenova Holding GmbH was created in 2008 as a result of the merger of Dragenopharm Apotheker Püschl GmbH and SWISS CAPS AG. It is now the parent company of both these organisations within the Aenova Group. Other companies have gradually been incorporated into the Aenova Group, including Euro Vital Pharma and the Temmler Group. CEO and Managing Director of Aenova Holding Gmbh is Heiner Hoppman, interviewed by Pharma World Magazine with Elisabeth Hartmann, Manager Corporate Communication, and Massimiliano Del Frate, Commercial and Logistic Director of Temmler Italia.
The needs of the users are more and more various, so the sector of pharmaceutical packaging has to diversify its own offer in order to fulfil them. Inge S.p.A., company owner of more than 280 international patents, has a constant and careful attention towards the market, and diversifies its offer accordingly. Inge Spa introduces today a new enema bottle, 30 ml capacity.
The company, that is specialized in the engineering and development of primary plastic packaging for the pharmaceutical, veterinary, cosmetic, nutraceutical, diagnostic and household product industries, set up this new bottle in soft LDPE (Low Density Poliethylene) replacing the usual seal with a special valve, that assures the non-return of the bottle to the initial position after use.
